What is Whitehawk Therapeutics Inc. Annual Revenue?

Whitehawk Therapeutics Inc. Annual Revenue rose 6.69%, in the last year to $25.98 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

What is Whitehawk Therapeutics Inc. Annual Net Profit?

Whitehawk Therapeutics Inc. Annual Net Profit rose 3.15% in the last year to $63.69 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

What is Whitehawk Therapeutics Inc. Price to Earning Ratio?

Whitehawk Therapeutics Inc. Price to Earning Ratio is -1.42, which is negative.

What is Whitehawk Therapeutics Inc. Stock Price?

Whitehawk Therapeutics Inc. Stock Price fell 10.14% and underperformed its sector by 17.13% in the past year.

What is Whitehawk Therapeutics Inc. Quarterly Revenue?

Whitehawk Therapeutics Inc. Quarterly Revenue rose 14.43% YoY to $7.24 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

What is Whitehawk Therapeutics Inc. Quarterly Net profit?

Whitehawk Therapeutics Inc. Quarterly Net profit fell 12.32% YoY to $18.27 M. Its sector's average net profit growth YoY for the quarter was -47.31%.

What is Whitehawk Therapeutics Inc. Mutual Fund Holding?

Whitehawk Therapeutics Inc. Mutual Fund Holding increased by 0.17% in the last quarter to 6.91.

What is Whitehawk Therapeutics Inc. Institutional Holding?

Whitehawk Therapeutics Inc. Institutional Holding remained the same in the last quarter at 55.95%.

How is the Whitehawk Therapeutics Inc. today?

The Whitehawk Therapeutics Inc. today is trading in the down by -1.52% at 1.95.

How has Whitehawk Therapeutics Inc. performed historically?

The Whitehawk Therapeutics Inc. is currently trading down -1.52% on an intraday basis in the past week the index fell -4.88%. The index has been down -33.90% in the past quarter and fell -10.14% in the past year. You can view this in the overview section.

Whitehawk Therapeutics Inc. XNAS: WHWK

Whitehawk Therapeutics Inc. Live Share Price Today, Share Analysis and Chart

Name: Whitehawk Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Whitehawk Therapeutics Inc.
Rating: 1.83216675
Author: Trendlyne DVM scores

Download real time

1.95 -0.03 (-1.52%)

48.82% Fall from 52W High

64,777 XNAS Volume

XNAS 25 Mar, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Whitehawk Therapeutics Inc. is on 27 Mar 2025 for the purpose of Whitehawk Therapeutics Inc Annual Report for 2024 See details

Whitehawk Therapeutics Inc. Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	90.3
PE TTM Negative PE TTM Unavailable in chosen country	-1.4
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.4
Price to Book Below industry Median Unavailable in chosen country	0.7
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	56
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	14.4
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	6.7
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-12.3
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	3.2
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-249.5
Piotroski Score High in industry Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-38.1

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

22.7 / 100

Technically Neutral

50.6 / 100

1Yr Price target upside is 3%

1 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Whitehawk Therapeutics Inc. Stock Price Analysis

Day Price Range -1.5% 1 Day return Unavailable in chosen country	2 (LTP) 1.92 LowHigh
Week Price Range -4.9% 1 Week return Unavailable in chosen country	2 (LTP) 1.82.2 LowHigh
Month Price Range -24.7% 1 Month return Unavailable in chosen country	2 (LTP) 1.82.7 LowHigh
52 Week Price Range -10.1% 1 Year return Unavailable in chosen country	2 (LTP) 1.23.8 LowHigh

View full Share Price History

Whitehawk Therapeutics Inc. Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Whitehawk Therapeutics Inc.'s Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-2.4

Avg. Estimate

-0.7

Low Estimate

-1.3

High Estimate

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 71.6% in FY25

Consensus Recommendation

2 ANALYST Recommendations

HOLD

The consensus recommendation from 2 analysts for Whitehawk Therapeutics Inc. is HOLD

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Whitehawk Therapeutics Inc. Stock Analysis

Whitehawk Therapeutics Inc. stock analysis with key metrics, changes, and trends.

Whitehawk Therapeutics Inc. Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$25.98 M	6.69%	positive	Annual Revenue rose 6.69%, in the last year to $25.98 M. Its sector's average revenue growth for the last fiscal year was 7.47%.
Annual Net Profit	$63.69 M	3.15%	positive	Annual Net Profit rose 3.15% in the last year to $63.69 M. Its sector's average net profit growth for the last fiscal year was -32.46%.
Price to Earning Ratio	-1.42	-	negative	Price to Earning Ratio is -1.42, which is negative.
Stock Price	$1.95	-10.14%	negative	Stock Price fell 10.14% and underperformed its sector by 17.13% in the past year.
Quarterly Revenue	$7.24 M	14.43%	positive	Quarterly Revenue rose 14.43% YoY to $7.24 M. Its sector's average revenue growth YoY for the quarter was 5.96%.
Quarterly Net profit	$18.27 M	12.32%	negative	Quarterly Net profit fell 12.32% YoY to $18.27 M. Its sector's average net profit growth YoY for the quarter was -47.31%.
Mutual Fund Holding	6.91 %	0.17%	positive	Mutual Fund Holding increased by 0.17% in the last quarter to 6.91.
Institutional Holding	55.95 %	0%	neutral	Institutional Holding remained the same in the last quarter at 55.95%.

VIEW LESS

Loading data..

Whitehawk Therapeutics Inc. - Company Profile

What does Whitehawk Therapeutics Inc. do?

Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

Whitehawk Therapeutics Inc. Management structure

All Gross Remunerations are in USD

Dr. Loretta Itri, M.D.

Chief Medical Officer

2024

Gross Remuneration

Year

Whitehawk Therapeutics Inc. Board of directors

All Gross Remunerations are in USD

Dr. Neil P. Desai,PhD

Director

2024

Gross Remuneration

Year

Dr. Caley Castelein, M.D.

Chairman of the Board

2024

Gross Remuneration

Year

Dr. Baiteng Zhao, PhD

Director

2024

Gross Remuneration

Year

Whitehawk Therapeutics Inc. Live Share Price Today, Share Analysis and Chart

48.82% Fall from 52W High

Whitehawk Therapeutics Inc. Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Whitehawk Therapeutics Inc. Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Whitehawk Therapeutics Inc. Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Whitehawk Therapeutics Inc.'s Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to grow by 71.6% in FY25

Consensus Recommendation

The consensus recommendation from 2 analysts for Whitehawk Therapeutics Inc. is HOLD

Whitehawk Therapeutics Inc. Stock Analysis

Whitehawk Therapeutics Inc. stock analysis with key metrics, changes, and trends.

Annual Revenue rose 6.69%, in the last year to $25.98 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit rose 3.15% in the last year to $63.69 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio is -1.42, which is negative.

Stock Price fell 10.14% and underperformed its sector by 17.13% in the past year.

Quarterly Revenue rose 14.43% YoY to $7.24 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit fell 12.32% YoY to $18.27 M. Its sector's average net profit growth YoY for the quarter was -47.31%.

Mutual Fund Holding increased by 0.17% in the last quarter to 6.91.

Institutional Holding remained the same in the last quarter at 55.95%.

Whitehawk Therapeutics Inc. - Company Profile

What does Whitehawk Therapeutics Inc. do?

Whitehawk Therapeutics Inc. Management structure

Dr. Loretta Itri, M.D.

Chief Medical Officer

Whitehawk Therapeutics Inc. Board of directors

Dr. Neil P. Desai,PhD

Director

Dr. Caley Castelein, M.D.

Chairman of the Board

Dr. Baiteng Zhao, PhD

Director

Whitehawk Therapeutics Inc. FAQ

How is Whitehawk Therapeutics Inc. today?

Whitehawk Therapeutics Inc. today is trading in the red, and is down by -1.52% at 1.95.

How has Whitehawk Therapeutics Inc. performed historically?

Whitehawk Therapeutics Inc. is currently trading down -1.52% on an intraday basis. In the past week the stock fell -4.88%. stock has been down -33.90% in the past quarter and fell -10.14% in the past year. You can view this in the overview section.